<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="806">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00183261</nctid>
  <trial_identification>
    <studytitle>Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection</studytitle>
    <scientifictitle>A Randomized Phase II Study of Therapeutic Immunization and Treatment Interruption Among Subjects Who Began Potent Antiretroviral Therapy Within 30 Days of Diagnosis of Acute or Recent HIV Infection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>10025</secondaryid>
    <secondaryid>AIN504/A5218</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - MRKAd5 HIV-1 gag/pol/nef
Other interventions - MRKAd5 HIV-1 gag/pol/nef placebo

Experimental: 1 - Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine at study entry and on Weeks 4 and 26

Placebo Comparator: 2 - Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine placebo at study entry and on Weeks 4 and 26


Other interventions: MRKAd5 HIV-1 gag/pol/nef
1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly

Other interventions: MRKAd5 HIV-1 gag/pol/nef placebo
1.0 mL administered intramuscularly

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Average of log10 HIV-1 RNA viral load</outcome>
      <timepoint>At Weeks 58 and 63</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Frequency of Grade 3 or 4 systemic adverse events, the occurrence of a severe or life-threatening injection site adverse event, or death</outcome>
      <timepoint>Throughout study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Distribution of plasma HIV RNA viral load</outcome>
      <timepoint>At Weeks 63 and 87</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with controlled viremia and their respective distribution of plasma HIV RNA viral load</outcome>
      <timepoint>At Weeks 63 and 87</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean viral burden, defined as time-averaged area under the log10 HIV-1 RNA viral load curve</outcome>
      <timepoint>At Weeks 63 and 87</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HIV DNA levels</outcome>
      <timepoint>At Weeks 30, 38, 63, and 87</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HIV-1 DNA levels</outcome>
      <timepoint>At Weeks 30, 38, 46, 50, 63, and 87</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Magnitude and absolute change in CD4 and CD8 counts</outcome>
      <timepoint>At Weeks 63 and 87</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent and absolute change in the number of HIV-1- specific CD8 cells, as measured by interferon (IFN)-gamma Elispot assay and intracellular cytokine staining</outcome>
      <timepoint>Through Week 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent and absolute change in the cytokine secretion patterns and the proliferative capacity of HIV-1- specific CD4 and CD8 cells, as measured by multiparameter flow cytometry</outcome>
      <timepoint>Through Week 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Breadth and magnitude of HIV-1- specific CD4 and CD8 cell responses</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to reach the specified virologic or immunologic criteria for reinitiating antiretroviral therapy after treatment interruption</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of Grade 3 or 4 systemic adverse events or the occurrence of a severe or life-threatening injection site adverse event, or HIV-related events, AIDS-defining infections, and death from time of vaccination</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cell-associated infectivity in latently infected cells</outcome>
      <timepoint>At Week 63</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cell-associated infectivity at Week 63 and immunologic responses</outcome>
      <timepoint>At Weeks 63 and 87</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Initiated HAART within 30 days of an acute or recent HIV-1 infection diagnosis. More
             information on this criterion can be found in the protocol.

          -  Initiated HAART within 30 days of documented acute or recent HIV-1 infection without
             interruption for more than 7 days

          -  Sustained viral suppression, defined as a viral load of 500 copies/mL or less 12
             months prior to baseline with an undetectable HIV-1 RNA viral load between 60 to 7
             days prior to baseline

          -  CD4 count of 450 cells/mm3 or more OR 35% or more between 60 to 14 days prior to
             baseline

          -  Ad5 neutralizing antibody titer of 200 or less at screening

          -  Willing to follow all study procedures and schedules

          -  Willing to interrupt HAART for at least 24 weeks following completion of the
             vaccination stage

          -  Negative for hepatitis B surface antigen (HBsAg) at screening

          -  Willing to use acceptable forms of contraception

          -  Infected with HIV-1 subtype B, if this information is available</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Virologic relapse, defined as 2 consecutive measurements of viral load of 500
             copies/mL or more at least 7 days apart within 12 months of baseline visit

          -  Received more than 7 days of continuous HAART other than that received within 16 days
             of acute or recent HIV-1 infection. Participants who received HAART as part of
             post-exposure prophylaxis (PEP) more than 6 months prior to the start of initial HAART
             may be eligible, provided that they did not acquire HIV-1 infection from the event
             that required PEP.

          -  History of anaphylaxis or allergy to vaccine components, including Tris buffer,
             magnesium chloride, and polysorbate 80 (Tween)

          -  History of clinically significant heart, lung, kidney, liver, pancreatic,
             gastrointestinal, or neurological disease that, in the opinion of the study
             investigator, may interfere with the study

          -  Contraindication to intramuscular (IM) injection, such as anticoagulant therapy or
             thrombocytopenia

          -  Receipt of any immune globulin or blood products within 3 months prior to baseline

          -  Receipt of any live vaccine within 30 days prior to baseline or any inactivated
             vaccine within 14 days prior to baseline

          -  Previous receipt of any HIV vaccine. Participants that were documented to have
             received only placebo are not excluded.

          -  History of any AIDS-defining illness. If a participant's sole AIDS-defining illness is
             Kaposi's sarcoma limited to the skin and is not anticipated to require systemic
             chemotherapy, that participant is not excluded.

          -  Currently receiving drugs or biologics not approved by the Food and Drug
             Administration (FDA) other than investigational HIV medications

          -  Current or past participation in other studies that might alter the participant's
             response to the study vaccination

          -  Use of any immunomodulatory agents, including but not limited to interleukin-2 (IL-2),
             granulocyte/macrophage-colony stimulating factor (GM-CSF), and systemic
             corticosteroids, within 30 days prior to baseline

          -  Active alcohol or substance use that, in the investigator's opinion, may interfere
             with the study

          -  Any other criteria or condition that, in the investigator's opinion, may interfere
             with the study

          -  Unwilling or unable to contribute to the planned peripheral blood mononuclear cell
             (PBMC) blood collection

          -  Pregnancy or breastfeeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>25</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Holdsworth House Medical Practice CRS - Darlinghurst</hospital>
    <hospital>St. Vincent's Hospital CRS - Darlinghurst</hospital>
    <hospital>Taylor Square Private Clinic CRS - Darlinghurst</hospital>
    <hospital>AIDS Research Initiative, Darlinghurst CRS - Darlinghurst</hospital>
    <hospital>407 Doctors (Australia) AIEDRP - Sydney</hospital>
    <hospital>AIDS Research Initiative (Australia) AIEDRP - Sydney</hospital>
    <hospital>St. Vincent's Hosp. (Australia) AIEDRP - Sydney</hospital>
    <hospital>Taylor Square Private Clinic (Australia) AIEDRP - Sydney</hospital>
    <hospital>Holdsworth House Gen. Practice (Australia) AIEDRP - Sydney</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode> - Darlinghurst</postcode>
    <postcode>2010 - Sydney</postcode>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>American Samoa</country>
      <state>Surry Hills</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Institute of Allergy and Infectious Diseases (NIAID)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Acute Infection and Early Disease Research Program</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>AIDS Clinical Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether the HIV vaccine MRKAd5 HIV-1 gag/pol/nef
      followed by treatment interruption can increase immune system function in adults with acute
      or recent HIV infection who have started taking anti-HIV drugs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00183261</trialwebsite>
    <publication>Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, Deschenes GR, Ramanathan M Jr, Barsoum S, Vanderhoeven J, He T, Chung C, Murray J, Perelson AS, Zhang L, Ho DD. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis. 2002 Sep 1;186(5):634-43. Epub 2002 Aug 9.
Moss RB, Brandt C, Giermakowska WK, Savary JR, Theofan G, Zanetti M, Carlo DJ, Wallace MR. HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine. 2003 Mar 7;21(11-12):1066-71.
Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 2000 Sep;182(3):766-75. Epub 2000 Aug 17.
Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000 Sep 28;407(6803):523-6.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Susan Little, MD</name>
      <address>University of California, San Diego AIDS Vaccine Research Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>